Atrial fibrillation (AF) is one of the most common rhythm disorders observed in clinical practice and is predominantly associated with coronary heart disease and hypertension. However, different classes of drugs may induce AF as a side effect in patients without apparent heart disease or they may precipitate the onset of AF in patients with preexisting heart disease. This case report includes etoricoxib-induced acute AF in a patient with hypertension.
Introduction
Atrial fibrillation (AF) is one of the most common abnormal heart rhythm disorders characterized by the rapid and irregular beating of atria. Most of the time AF episodes have no symptoms. Sometimes there may be palpitations, fainting attacks, lightheadedness, and shortness of breath, chest pain, or chest tightness [1] . It is associated with an increased risk of heart failure, stroke, and dementia.
Hypertension and valvular heart disease are the most common modifiable risk factors for AF [2, 3] . Other heart-related risk factors are heart failure, coronary artery disease, cardiomyopathy, and congenital heart disease. Noncardiac risk factors include COPD, obesity, sleep apnea, drug-induced AF, excess alcohol intake, tobacco smoking, diabetes mellitus, and thyrotoxicosis. Here we report a female patient who presented to the emergency department with an acute attack of AF: possibly a drug-induced adverse effect following the history of intake of etoricoxib for 2 days for musculoskeletal pain.
Case Report
A 62-year-old female patient presented to the emergency department with a history of sudden onset pain on the left side of the chest and palpitations of 5-to 6-h duration with progressive course. There was no history suggestive of dyspnea, orthopnea, syncope, previous history of similar attacks, headache, or fever.
The patient was a known case of primary hypertension on regular treatment. She was not taking any diuretic drug. The previous year she was diagnosed with right adrenal gland adenoma for which she was on regular follow-up with the endocrinology department. Her latest catecholamine, metanephrine, and normetanephrine levels were within normal limits. She had undergone cervical disc surgery in the past and was having chronic neck pain and osteoarthritis of the knees for which she This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. DOI: 10.1159/000502451 was on analgesics as required. On enquiry, she revealed that she was prescribed etoricoxib tablets for leg pain which she took for 2-3 days before presenting to the accident and emergency department.
On arrival, she was anxious, with HR > 160/min, irregular pulse, blood pressure 150/70 mm Hg, RR 18-20/min, maintaining SpO 2 99% on room air. Her systemic examination revealed no abnormalities. A 12-lead ECG showed AF with rapid ventricular rate > 160 ( Fig. 1 ). Serial cardiac markers, septic markers, renal profile, and electrolytes were within normal limits.
She was treated initially with intravenous (i.v.) metoprolol 10 mg in incremental doses of 5mg. She was then started on chemical cardioversion with a loading dose of amiodarone 300 mg i.v., after which HR reduced to around 110-120/min. However, her rhythm remained irregular. Blood pressure was stable, and she was administered with aspirin tablets 300 mg stat and injection of enoxaparin 80 mg s.c. for anticoagulation, subsequently administered twice daily. Amiodarone infusion 1 mg/min i.v. for 6 h and then 0.5 mg/min i.v. over the next 18 h was started by the cardiologist in the medical ICU (MICU). The injection of amiodarone was then converted to oral amiodarone 200 mg every 8 h. She was also receiving amlodipine tablets 5 mg, rosuvastatin 20 mg, and bisoprolol 2.5 mg during her stay in the ICU. Bedside 2D-ECHO revealed mild left atrial and right ventricular dilatation with concentric left ventricular hypertrophy. After around 40 h of medical management and observation in the MICU, she reverted to a sinus rhythm with HR 60-68/min (Fig. 2) . The patient was observed for a few hours in the MICU and was then transferred to the ward for further management.
Discussion
AF is one of the most common arrhythmias and is an important cause of hospitalization and morbidity. Many drugs can cause AF as a side effect. However, drug-induced AF is less recognized. In our case the causality assessment as per Naranjo's algorithm [4, 5] (Appendix 1-A) and WHO-UMC criteria [6] (Appendix1-B) revealed an adverse drug reaction (ADR) to be "possible." The patient's recent medication with etoricoxib led us to conclude a possible diagnosis of exclusion as drug-induced AF. Hence, this report is an attempt to bring attention to this adverse drug effect. In most cases, druginduced AF is paroxysmal and terminates spontaneously, but sometimes it persists and requires cardioversion to restore the sinus rhythm and avoid progression to persistent AF. Because of the short duration, and in ad- dition to less attention given to this side effect, the exact incidence and clinical consequences of drug-induced AF are presently unknown.
Being one of the leading causes of morbidity and mortality among hospitalized patients, ADRs are a matter of health concern. Reports from various studies confer that approximately 8% of cases among all hospitalizations are due to ADRs [7] .
Etoricoxib is a selective cyclo-oxygenase 2 (COX-2) enzyme inhibitor and is used for its analgesic activity in various inflammatory disease conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, chronic low back pain, and in cases of acute pain. Our review of the literature on NSAIDs has shown that NSAIDs are associated with increased risk of AF [8] .
The combined results of several large epidemiologic studies suggest that the use of non-aspirin NSAIDs is associated with a 12% increase in the risk of AF [9] . In a nation-wide, population-based cohort of 7 million subjects, meta-analyses were performed for different cardiovascular outcomes; coxib use was associated with an increased risk for a first episode of AF. A post hoc anal-ysis of different coxibs revealed a significant association with incident AF for etoricoxib [10] . Tissue-selective deletion of COX-2 has revealed an unexpected role for the cardiomyocyte enzyme in the modulation of cardiac rhythm and function. Inhibition of COX-2 in cardiomyocytes may have contributed to the spectrum of cardiovascular hazard that complicates therapy with NSAIDs [11] .
Conclusion
Drug-induced AF is a separate entity that needs awareness amongst physicians for successful management of patients. In order to prevent ADRs we recommend education, surveillance, and monitoring of patients. ADRs should be recorded in patient files and communicated to patients. Patients should be advised on the risks of selfmedication. 
